)
)
Tyme Investor Relations Material
Latest events
Q3 2022
Tyme
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Tyme Technologies Inc
Access all reports
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) for patients with a broad range of cancers. The company is developing THOR, a synthetic retinoid prodrug designed to be an orally active anticancer agent in the treatment of cancers. It offers Thymidylate synthase (TYMS) inhibitors and other chemicals used in research. The company has clinical stage product candidates under clinical development and preclinical stage programs under nonclinical development.
Latest articles
)
Mercado Libre: The Digital Backbone of Latin America
From shopping to logistics and fintech, Mercado Libre is shaping the digital transformation of Latin America.
3 Jan 2025
)
House of Pinault: The History and Business of Kering and Gucci
Kering is a luxury group under the Pinault family's leadership, managing iconic brands like Gucci, Saint Laurent, and Bottega Veneta.
19 Dec 2024
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
Ticker symbol
TYME
Country
🇺🇸 United States